Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin

BMC Neuroscience

Volumn 13, Issue 1, 2012, Pages

  Last, Victoria ^a,b   Williams, Alun ^a,c   Werling, Dirk ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Neurotoxicity; PACOCF3; Phospholipase A2; Prions; Synaptophysin

Indexed keywords

BETA III TUBULIN; CYTOSOLIC PHOSPHOLIPASE A2; ENZYME INHIBITOR; F ACTIN; PALMITOYL TRIFLUOROMETHYL KETONE; PRION PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN NERVE CELL; CELL DEATH; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; ENZYME INHIBITION; NERVE CELL LESION; NEURITE; PATHOGENESIS; PERIKARYON; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SYNAPSE;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACID; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; IONOMYCIN; KETONES; MICE; NEURONS; PEPTIDE FRAGMENTS; PHOSPHOLIPASES A2, CYTOSOLIC; PRIONS; PROTEIN TRANSPORT; SYNAPTOPHYSIN; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRITIUM; TUBULIN;

EID: 84865342901     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-13-106     Document Type: Article

References (60)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144. 10.1126/science.6801762, 6801762.
2. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 1993, 362:543-546. 10.1038/362543a0, 8464494.
3. Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996, 380:345-347. 10.1038/380345a0, 8598929.
4. Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, Beyreuther K, Masters CL, Collins SJ, Cappai R. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 2001, 65:565-572. 10.1002/jnr.1186, 11550224.
5. Yang L, Zhou X, Yang J, Yin X, Han L, Zhao D. Aspirin inhibits cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with microglia activation in vitro. J Neuroimmunol 2008, 199:10-17. 10.1016/j.jneuroim.2008.04.028, 18547651.
6. Selvaggini C, De Gioia L, Cantù L, Ghibaudi E, Diomede L, Passerini F, Forloni G, Bugiani O, Tagliavini F, Salmona M. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun 1993, 194:1380-1386. 10.1006/bbrc.1993.1977, 8102526.
7. Gu Y, Fujioka H, Mishra RS, Li R, Singh N. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 2002, 277:2275-2286. 10.1074/jbc.M104345200, 11682469.
8. Brown DA. PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochem J 2000, 352:511-518. 10.1042/0264-6021:3520511, 1221483, 11085945.
9. Thellung S, Villa V, Corsaro A, Arena S, Millo E, Damonte G, Benatti U, Tagliavini F, Florio T, Schettini G. p38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells. Neurobiol Dis 2002, 9:69-81. 10.1006/nbdi.2001.0461, 11848686.
10. Diomede L, Sozzani S, Luini W, Algeri M, De Gioia L, Chiesa R, Lievens PM, Bugiani O, Forloni G, Tagliavini F, Salmona M. Activation effects of a prion protein fragment PrP-(106-126) on human leucocytes. Biochem J 1996, 320:563-570. 1217966, 8973567.
11. Williams A, Van Dam AM, Ritchie D, Eikelenboom P, Fraser H. Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res 1997, 754:171-180. 10.1016/S0006-8993(97)00067-X, 9134973.
12. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJE, Knight R, Pocchiari M. Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease. Neurology 2002, 58:127-129. 10.1212/WNL.58.1.127, 11781418.
13. Bate C, Reid S, Williams A. Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem 2004, 279:36405-36411. 10.1074/jbc.M404086200, 15210691.
14. Farooqui AA, Horrocks LA. Brain phospholipases A2: a perspective on the history.Prostaglandins, Leukotrienes, Essent. Fatty Acids 2004, 71:161-169.
15. Sun GY, Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 2004, 45:205-213.
16. Brown WJ, Chambers K, Doody A. Phospholipase A2 (PLA2) enzymes in membrane trafficking: mediators of membrane shape and function. Traffic 2003, 4:214-221. 10.1034/j.1600-0854.2003.00078.x, 12694560.
17. Murakami M, Nakatani Y, Kuwata H, Kudo I. Cellular components that functionally interact with signaling phospholipase A2s. Biochim Biophys Acta 2000, 1488:159-166. 10.1016/S1388-1981(00)00118-9, 11080685.
18. Balsinde J, Winstead MV, Dennis EA. Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett 2002, 531:2-6. 10.1016/S0014-5793(02)03413-0, 12401193.
19. Kramer RM, Sharp JD. Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). FEBS Lett 1997, 410:49-53. 10.1016/S0014-5793(97)00322-0, 9247121.
20. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278. 10.1016/0092-8674(93)90666-E, 8381049.
21. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, Gelb MH. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem 2000, 275:37542-37551. 10.1074/jbc.M003395200, 10978317.
22. Bate C, Salmona M, Williams A. The role of platelet activating factor in prion and amyloid-β neurotoxicity. Neuroreport 2004, 15:509-513. 10.1097/00001756-200403010-00025, 15094513.
23. Schievella AR, Regier MK, Smith WL, Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 1995, 270:30749-30754. 10.1074/jbc.270.51.30749, 8530515.
24. Bonventre JV, Gronich JH, Nemenoff RA. Epidermal growth factor enhances glomerular mesangial cell soluble phospholipase A2 activity. J Biol Chem 1990, 265:4934-4938.
25. Lin LL, Lin AY, Knopf JL. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proceedings of the National Academy of Sciences USA 1992, 89:6147-6151.
26. Ghosh M, Stewart A, Tucker DE, Bonventre JV, Murphy RC, Leslie CC. Role of cytosolic phospholipase A2 in prostaglandin E2 production by lung fibroblasts. Am J Respir Cell Mol Biol 2004, 30:91-100.
27. Conde-Frieboes K, Reynolds LJ, Lio Y-C, Hale MR, Wasserman HH, Dennis EA. Activated ketones as inhibitors of intracellular Ca2+-dependent and Ca2+-independent phospholipase A2. J Am Chem Soc 1996, 118:5519-5525.
28. Bate C, Boshuizen R, Williams A. Microglial cells kill prion-damaged neurons in vitro by a CD14 dependent process. J Neuroimmunol 2005, 170:62-70. 10.1016/j.jneuroim.2005.08.021, 16225933.
29. Kitamoto T, Shin R, Doh-ura K, Tomokane N, Miyazono M, Muramoto T, Tateishi J. Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol 1992, 140:1285-1294. 1886543, 1351366.
30. Ferrer I, Puig B, Blanco R, Marti E. Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt-Jakob disease. Neuroscience 2000, 97:715-726. 10.1016/S0306-4522(00)00045-2, 10842016.
31. Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljärvi L, Koivisto E, Riekkinen PJ. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in alzheimer's disease. Neuroscience 1995, 64:375-384. 10.1016/0306-4522(94)00422-2, 7700527.
32. Nieznanski K, Podlubnaya ZA, Nieznanska H. Prion protein inhibits microtubule assembly by inducing tubulin oligomerization. Biochem Biophys Res Commun 2006, 349:391-399. 10.1016/j.bbrc.2006.08.051, 16934224.
33. Hirabayashi T, Shimizu T. Localization and regulation of cytosolic phospholipase A2. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of, Lipids 2000, 1488:124-138.
34. Glover S, Bayburt T, Jonas M, Chi E, Gelb MH. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem 1995, 270:15359-15367. 10.1074/jbc.270.25.15359, 7797525.
35. Perisic O, Paterson HF, Mosedale G, Lara-Gonzalez S, Williams RL. Mapping the phospholipid-binding surface and translocation determinants of the C2 domain from cytosolic phospholipase A2. J Biol Chem 1999, 274:14979-14987. 10.1074/jbc.274.21.14979, 10329700.
36. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987, 51:229-240. 10.1016/0092-8674(87)90150-4, 2444340.
37. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998, 279:827-834. 10.1126/science.279.5352.827, 9452375.
38. Wilson R, Bate C, Boshuizen R, Williams A, Brewer J. Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide. BMC Neurosci 2007, 8:99. 10.1186/1471-2202-8-99, 2131757, 18034899.
39. Bate C, Williams A. Neurodegeneration induced by the clustering of sialylated glycosylphosphatidylinositols of prion proteins. J Biol Chem 2012,
40. Brown DR, Schmidt B, Kretzschmar HA. Prion protein fragment interacts with PrP-deficient cells. J Neurosci Res 1998, 52:260-267. 10.1002/(SICI)1097-4547(19980501)52:3<260::AID-JNR2>3.0.CO;2-B, 9590434.
41. Nieznanski K, Nieznanska H, Skowronek KJ, Osiecka KM, Stepkowski D. Direct interaction between prion protein and tubulin. Biochem Biophys Res Commun 2005, 334:403-411. 10.1016/j.bbrc.2005.06.092, 16004966.
42. Keshet G, Bar-Peled O, Yaffe D, Nudel U, Gabizon R. The cellular prion protein colocalizes with the dystroglycan complex in the brain. J Neurochem 2000, 75:1889-1897.
43. Giorgi A, Francesco LD, Principe S, Mignogna G, Sennels L, Mancone C, Alonzi T, Sbriccoli M, Pascalis AD, Rappsilber J, Cardone F, Pocchiari M, Maras B, Schininà ME. Proteomic profiling of PrP27-30-enriched preparations extracted from the brain of hamsters with experimental scrapie. Proteomics 2009, 9:3802-3814. 10.1002/pmic.200900085, 19637240.
44. Fatima S, Yaghini FA, Pavicevic Z, Kalyankrishna S, Jafari N, Luong E, Estes A, Malik KU. Intact actin filaments are required for cytosolic phospholipase A2 translocation but not for its activation by norepinephrine in vascular smooth muscle cells. J Pharmacol Exp Ther 2005, 313:1017-1026. 10.1124/jpet.104.081992, 15705737.
45. Nakata T, Hirokawa N. Microtubules provide directional cues for polarized axonal transport through interaction with kinesin motor head. J Cell Biol 2003, 162:1045-1055. 10.1083/jcb.200302175, 2172855, 12975348.
46. Hachiya NS, Watanabe K, Yamada M, Sakasegawa Y, Kaneko K. Anterograde and retrograde intracellular trafficking of fluorescent cellular prion protein. Biochem Biophys Res Commun 2004, 315:802-807. 10.1016/j.bbrc.2004.01.126, 14985083.
47. Moya KL, Hässig R, Créminon C, Laffont I, Giamberardino LD. Enhanced detection and retrograde axonal transport of PrPC in peripheral nerve. J Neurochem 2004, 88:155-160.
48. Borchelt DR, Koliatsos VE, Guarnieri M, Pardo CA, Sisodia SS, Price DL. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem 1994, 269:14711-14714.
49. Bate C, Tayebi M, Williams A. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol 2008, 6:8. 10.1186/1741-7007-6-8, 2270799, 18269734.
50. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8:413-450. 10.1023/A:1025513106330, 12975575.
51. Bate C, Tayebi M, Williams A. A glycosylphosphatidylinositol analogue reduced prion-derived peptide mediated activation of cytoplasmic phospholipase A2, synapse degeneration and neuronal death. Neuropharmacology 2010, 59:93-99. 10.1016/j.neuropharm.2010.04.002, 20398681.
52. Ferrer I, Rivera R, Blanco R, Martí E. Expression of proteins linked to exocytosis and neurotransmission in patients with Creutzfeldt-Jakob disease. Neurobiol Dis 1999, 6:92-100. 10.1006/nbdi.1998.0226, 10343324.
53. Jeffrey M, Halliday WG, Bell J, Johnston AR, Macleod NK, Ingham C, Sayers AR, Brown DA, Fraser JR. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 2000, 26:41-54. 10.1046/j.1365-2990.2000.00216.x, 10736066.
54. Shimizu M, Azuma C, Taniguchi T, Murayama T. Expression of cytosolic phospholipase A2 alpha; in murine C12 cells, a variant of L929 cells, induces arachidonic acid release in response to phorbol myristate acetate and Ca2+ ionophores, but not to tumor necrosis factor-alpha. J Pharmacol Sci 2004, 96:324-332. 10.1254/jphs.FPJ04033X, 15539760.
55. Xue D, Xu J, McGuire SO, Devitre D, Sun GY. Y: Studies on the cytosolic phospholipase A2 in immortalized astrocytes (DITNC) revealed new properties of the calcium ionophore, A23187. Neurochem Res 1999, 24:1285-1291. 10.1023/A:1020981224876, 10492524.
56. Williams A, Lucassen PJ, Ritchie D, Bruce M. PrP deposition, microglial activation and neuronal apoptosis in murine scrapie. Exp Neurol 1997, 144:433-438. 10.1006/exnr.1997.6424, 9168844.
57. Ackermann EJ, Conde-Frieboes K, Dennis EA. Inhibition of macrophage Ca2+ independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 1995, 270:445-450. 10.1074/jbc.270.1.445, 7814408.
58. Trimble L, Street I, Perrier H, Tremblay N, Weech P, Bernstein M. NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A2/. Biochemistry 1993, 32:12560-12565. 10.1021/bi00210a002, 8251473.
59. Manson J, Clarke A, Hooper M, Aitchison L, McConnell I, Hope J. 129/Ola mice carryling a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994, 8:121-127. 10.1007/BF02780662, 7999308.
60. Bate C, Boshuizen R, Langeveld J, Williams A. Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport 2002, 13:1695-1700. 10.1097/00001756-200209160-00025, 12352629.